These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1245 related articles for article (PubMed ID: 20797419)

  • 1. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
    Danhier F; Feron O; Préat V
    J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive and active drug targeting: drug delivery to tumors as an example.
    Torchilin VP
    Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer drug delivery with nanoparticles.
    Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
    In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in polymeric micelles for drug delivery and tumor targeting.
    Kedar U; Phutane P; Shidhaye S; Kadam V
    Nanomedicine; 2010 Dec; 6(6):714-29. PubMed ID: 20542144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nanocarrier systems in cancer nanotherapy.
    Mozafari MR; Pardakhty A; Azarmi S; Jazayeri JA; Nokhodchi A; Omri A
    J Liposome Res; 2009; 19(4):310-21. PubMed ID: 19863166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis.
    Huang S; Shao K; Liu Y; Kuang Y; Li J; An S; Guo Y; Ma H; Jiang C
    ACS Nano; 2013 Mar; 7(3):2860-71. PubMed ID: 23451830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
    J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
    Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic nanocarriers for cancer drug delivery.
    López-Dávila V; Seifalian AM; Loizidou M
    Curr Opin Pharmacol; 2012 Aug; 12(4):414-9. PubMed ID: 22465543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
    Talekar M; Kendall J; Denny W; Garg S
    Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active targeting of brain tumors using nanocarriers.
    Béduneau A; Saulnier P; Benoit JP
    Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle and targeted systems for cancer therapy.
    Brannon-Peppas L; Blanchette JO
    Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallic nanoparticles: technology overview & drug delivery applications in oncology.
    Ahmad MZ; Akhter S; Jain GK; Rahman M; Pathan SA; Ahmad FJ; Khar RK
    Expert Opin Drug Deliv; 2010 Aug; 7(8):927-42. PubMed ID: 20645671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
    Sultana S; Khan MR; Kumar M; Kumar S; Ali M
    J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.